Improve blood sugar tolerance in patients with type 2 diabetes, and reduce basal and postprandial blood sugar. It can reduce the production of glycogen, reduce intestinal absorption of sugar, and increase insulin sensitivity by increasing peripheral sugar uptake and utilization. It will not cause hypoglycemia in patients with type 2 diabetes or patients with normal blood sugar (except in special circumstances). After treatment, insulin secretion remains unchanged, while fasting insulin levels and daily plasma insulin levels are reduced.

Improve blood sugar tolerance in patients with type 2 diabetes, reduce basal and postprandial blood sugar; reduce liver sugar production, reduce intestinal absorption of sugar, increase peripheral sugar uptake and utilization, and improve insulin sensitivity; will not cause hypoglycemia in patients with type 2 diabetes or patients with normal blood sugar (except in special circumstances). After treatment, insulin secretion remains unchanged, while fasting insulin levels and daily plasma insulin levels are reduced.

Participates in bone formation and reconstruction of bone tissue after fracture, as well as muscle contraction, nerve transmission, coagulation mechanism and reduces capillary permeability, etc.

This product is a competitive angiotensin converting enzyme inhibitor, which prevents angiotensin I from converting into angiotensin II, thereby reducing peripheral vascular resistance and reducing water and sodium retention by inhibiting aldosterone secretion. This product can also dilate peripheral blood vessels by interfering with the degradation of bradykinin. For patients with heart failure, this product can also reduce pulmonary capillary wedge pressure and pulmonary vascular resistance, increase cardiac output and exercise tolerance time.